Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Cash from Financing Activities across 10 years of filings, most recently posting $13.0 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 100.75% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$394.0 million (up 88.36% YoY) and the FY2025 annual result came in at -$2.2 billion, down 20.1% from the prior year.
• Cash from Financing Activities slipped to $13.0 million in Q1 2026, from $40.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $40.0 million in Q4 2025 and troughed at -$1.7 billion in Q1 2025.
• A 5-year average of -$458.0 million and a median of -$446.0 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 35400.0% — and 2025, when it soared 105.93%.
• Tracing TEVA's Cash from Financing Activities over 5 years: stood at -$711.0 million in 2022, then gained by 18.99% to -$576.0 million in 2023, then decreased by 17.01% to -$674.0 million in 2024, then jumped by 105.93% to $40.0 million in 2025, then plunged by 67.5% to $13.0 million in 2026.
• Business Quant data shows TEVA's Cash from Financing Activities at $13.0 million in Q1 2026, $40.0 million in Q4 2025, and -$453.0 million in Q3 2025.